Why Gain Therapeutics, Inc.’s (GANX) Stock Is Up 8.49%
As of Thursday, August 13, Gain Therapeutics, Inc.’s GANX share price has surged by 8.49%, which has investors questioning if this is right time to sell.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. The company’s drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. Its lead drug candidate is GT-02287, which is currently in a Phase 1b study for the treatment of Parkinson’s disease with or without a GBA1 mutation. The company has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of dementia with Lewy bodies, Alzheimer's disease, and Gaucher’s disease, lysosomal storage disorders, metabolic disorders, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is based in Bethesda, Maryland.
Commentary & Analysis
Why Gain Therapeutics, Inc.’s (GANX) Stock Is Up 11.32%
As of Thursday, August 13, Gain Therapeutics, Inc.’s GANX share price has surged by 11.32%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Gain Therapeutics, Inc.’s (GANX) Stock Is Up 13.56%
As of Tuesday, August 11, Gain Therapeutics, Inc.’s GANX share price has surged by 13.56%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Gain Therapeutics, Inc.’s (GANX) Stock Is Up 19.21%
As of Tuesday, August 11, Gain Therapeutics, Inc.’s GANX share price has surged by 19.21%, which has investors questioning if this is right time to sell.Tudor Pop
Why Gain Therapeutics, Inc.’s (GANX) Stock Is Down 5.38%
As of Tuesday, July 28, Gain Therapeutics, Inc.’s GANX share price has dipped by 5.38%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Financial Summary
| Share Statistics | GANX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $80.3 | $259.1 | 19% |
|
| Shares Out (Mil) | 42.9 | 54.3 | 44% |
|
| Institutional Ownership | 89.8% | 92.8% | 57% |
|
| Float (Mil) | 42.6 | 42.0 | 44% |
|
| Beta | 0.20 | 0.95 | 13% |
|
| Avg Daily Volume (000s) | 361 | 637 | 51% |
|
| Price Change (52-week) |
5.8% | 52.5% | 57% |
|
| Growth | GANX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.2% | na |
|
| Net Income (5yr) | (41.2%) | (10.1%) | 9% |
|
| EPS (5yr) | 14.4% | 15.8% | 55 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (34.6%) | (15.6%) | 15% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 3 | 3 | 3 | |
| Current EPS | ($0.127) | ($0.497) | ($0.547) | |
| Month Ago EPS | ($0.127) | ($0.503) | ($0.543) | |
| # Rev Up | 2 | 1 | 1 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | ($0.158) | ($0.603) | ($0.600) | |
| Year/Year Chg | 16.5% | (18.8%) | 37.3% | |
| Financials | GANX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($20) | ($43) | 24% |
|
| EPS (TTM) | ($0.509) | ($1.600) | 27% |
|
| Operating Cash Flow (TTM) (Mil) | ($19) | ($32) | 15% |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 14% |
|
| Enterprise Value (Q1) (Mil) | $74 | $175 | 19% |
|
| Valuation | GANX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 7.08 | 2.54 | 86% |
|
| P/E | na | 18.4 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | GANX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 68.9% | na |
|
| Net Margin | na | (72.5%) | na |
|
| ROA | (159.2%) | (47.5%) | 3% |
|
| ROE | (268.3%) | (54.9%) | 3% |
|
| Liabilities to Assets | 26.8% | 29.4% | 18% |
|
| F-Score | 2 | 3 | 7% |
|
Gain Therapeutics, Inc. did not pass any screens on 9/23/2026.
